Cyberknife stereotactic radiotherapy as monotherapy for low to intermediate stage prostate cancer: Early experience, feasibility and tolerance

The Cyberknife, a linear accelerator mounted on a robotic device, enables excellent dose conformation to the target and minimizes dose to surrounding normal tissue. It is a very suitable device for performing hypofractionated stereotactic body radiotherapy (SBRT) as monotherapy for low to intermediate risk prostate cancer patients. We report our early experience using this technique.